Ovid Therapeutics (FRA:1OT) Valuation Rank

View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ovid Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovid Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (FRA:1OT) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

OVID:USA

Address

441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001

Website

https://www.ovidrx.com

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.